A New Option for Cardiorenal Protection for Patients with CKD in T2D

A New Option for Cardiorenal Protection for Patients with CKD in T2D is organized by Medtelligence.,,Released: 07/29/2022,Valid until: 07/29/2023,Description:,Diabetic nephropathy is one of the leading causes of end-stage renal disease (ESRD) and is associated with mortality and morbidity worldwide. Recent data on the use of nonsteroidal MRAs were presented at the European Society of Cardiology and other major meetings and were simultaneously published in major journals. Join our experts to explore these data and find out how you can better prevent the deterioration of renal function and improve cardiovascular outcomes in your patients across the spectrum of renal decline.,,Learning Objectives:,After participating in this educational activity, participants should be better able to:,• Assess the benefit-risk profiles of nonsteroidal mineralocorticoid receptor antagonists (MRAs) from recent studies of patients with chronic kidney disease (CKD) in type 2 diabetes (T2D),• Evaluate the potential impact of the latest clinical trial data in real-world practice for a broad spectrum of patients with CKD in T2D,• Review new pharmacological treatment options for patients with CKD in T2D